Products

  1. Home
  2. Products
  3. Bone & Mineral Metabolism
  4. IDKmonitor® Etanercept Free ADA ELISA

IDKmonitor® Etanercept Free ADA ELISA

$859.00

Available with Lead Time!

Method: ELISA
Sample Type (Matrix): Serum, EDTA Plasma
Sample Volume: 25 µl
Species: Human
Incubation time: 2h 15m
Size: 96 wells
Regulatory Status: For research use only in the U.S.
Kit Manual: Download

The IDKmonitor® Etanercept Free ADA ELISA is an enzyme immunoassay intended for the quantitative determination of free anti-drug antibodies (ADA) against etanercept (e.g. ENBREL®) in EDTA plasma and serum.

For research use only. Not for use in diagnostic procedures.

For Laboratory Professional Use Only.

This is the RUO version of Immundiagnostik part number K 9653.

We also offer the IDKmonitor® Etanercept Drug Level ELISA.

Test Principle of the IDKmonitor® Etanercept Free ADA ELISA

The IDKmonitor® Etanercept Free ADA ELISA is designed for the quantitative determination of free antibodies against etanercept (e. g. Enbrel®).

In the first incubation step, the free anti-therapeutic antibodies from the sample are bound to etanercept binding domains coated on the plate. To remove all unbound substances, a washing step is carried out. In a further incubation step, a peroxidase-labeled therapeutic antibody (conjugate) is added. After another washing step, to remove all unbound substances, the solid phase is incubated with the substrate, Tetramethylbenzidine (TMB). An acidic stop solution is then added.

The color converts to yellow. The absorbance of the color compound is determined photometrically at 450 nm. The intensity of the color is directly proportional to the amount of bound anti-etanercept (e. g. Enbrel®) antibodies from the sample. The results are evaluated by a cut-off control.

Additional information

Weight 35.5 oz
Dimensions 6.5 × 10 × 4.5 in
Social media & sharing icons powered by UltimatelySocial

Become an IDK Insider!

Join our mailing list to receive the latest news and updates from Immundiagnostik, Inc.

 
 
 
 

You have Successfully Subscribed!